Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53:1459–64.
Teuber SS, Beyer K. IgG to foods: a test not ready for prime time. Curr Opin Allergy Clin Immunol. 2007;7:257–8.
Wuthrich B. Unproven techniques in allergy diagnosis. J Investig Allergol Clin Immunol. 2005;15:86–90.
Ali A, Scoulios N, Ten N. A National Assessment of the usage, cost, and reimbursement of unconventional medical laboratory tests. J Altern Complement Med. 2014;20:A3–A4.
Fell PJ, Srn SS, Brostoff J. Cellular responses to food in irritable bowel syndrome- an investigation of the Alcat test. J Nutr Med. 1991;2:143–9.
Sangberg DH. A comparison of the ALCAT test for food reactions amongst 2 population sub-groups. Annals of Allergy. 1989;62:271.
Mylek D. ALCAT Test results in the treatment of respiratory and gastrointestinal symptoms, arthritis, skin and central nervous system. Rocz Akad Med Bialymst. 1995;40:625–9.
Akmal M, Khan SA, Khan A. The Effect of the ALCAT Test diet therapy for food sensitivity. Middle East J Fam Med. 2009;7
Angelini F, Marzatico F, Stesina G, Stefanini L, Bonuccelli A, Buonocore D, Rucci S, Tencone F. Rational management of food intolerance in elite soccer club. J Int Soc Sports Nutr. 2011;8:36.
Kleine-Tebbe J, Herold DA. Inappropriate test methods in allergy. Hautarzt. 2010;61:961–6.
Wuthrich B. History of food allergy. Chem Immunol Allergy. 2014;100:109–19.
Pasula MJ. The ALCAT test: in vitro procedure for determining food sensitivities. Folia Med Cracov. 1993;34:153–7.
Hoffmann-Sommergruber K, Pfeifer S, Bublin M. Applications of molecular diagnostic testing in food allergy. Curr Allergy Asthma Rep. 2015;15:56.
Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133:291–307. quiz 308
Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, Cooper SF, Fenton MJ, Arshad SH, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. J Allergy Clin Immunol. 2010;126:1105–18.
Shafer SL, Dexter F. Publication bias, retrospective bias, and reproducibility of significant results in observational studies. Anesth Analg. 2012;114:931–2.
Ali A, Weiss TR, McKee D, Scherban A, Khan S, Fields MR, Apollo D, Mehal WZ. Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial. BMJ Open Gastroenterol. 2017;4:e000164.
Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143:1158–72.
Galluzzi L, Bravo-San Pedro JM, Kroemer G. Necrosis: linking the Inflammasome to inflammation. Cell Rep. 2015;11:1501–2.
Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev. 2008;60:795–804.
Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell RA, Mehal WZ. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest. 2009;119:305–14.
Hoque R, Farooq A, Malik A, Trawick BN, Berberich DW, McClurg JP, Galen KP, Mehal W. A novel small-molecule enantiomeric analogue of traditional (−)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage. J Immunol. 2013;190:4297–304.
Garica-Martinez I, Santoro N, Chen Y, Hoque R, Ouyang X, Caprio S, Shlomchik MJ, Coffman RL, Candia A, Mehal WZ. Hepatocyte mitochondrial DNA drives non-alcoholic steatohepatitis by activation of TLR9. J Clin Investig. In Press
Dieker J, Schlumberger W, McHugh N, Hamann P, van der Vlag J, Berden JH. Reactivity in ELISA with DNA-loaded nucleosomes in patients with proliferative lupus nephritis. Mol Immunol. 2015;68:20–4.
Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G, DeMatteo RP. Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology. 2010;51:621–32.
Gschwendt M, Furstenberger G, Leibersperger H, Kittstein W, Lindner D, Rudolph C, Barth H, Kleinschroth J, Marme D, Schachtele C, et al. Lack of an effect of novel inhibitors with high specificity for protein kinase C on the action of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate on mouse skin in vivo. Carcinogenesis. 1995;16:107–11.
Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269:5241–8.
Garcia-Martinez I, Mehal WZ. DNA: adding injury to insult. Hepatology. 2015;61:35–6.
Leppanen T, Tuominen RK, Moilanen E. Protein kinase C and its inhibitors in the regulation of inflammation: inducible nitric oxide synthase as an example. Basic Clin Pharmacol Toxicol. 2014;114:37–43.
Gray RD, Lucas CD, Mackellar A, Li F, Hiersemenzel K, Haslett C, Davidson DJ, Rossi AG. Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps. J Inflamm (Lond). 2013;10:12.
Vertegaal AC, Kuiperij HB, Yamaoka S, Courtois G, van der Eb AJ, Zantema A. Protein kinase C-alpha is an upstream activator of the IkappaB kinase complex in the TPA signal transduction pathway to NF-kappaB in U2OS cells. Cell Signal. 2000;12:759–68.
Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME, First International Gastrointestinal Eosinophil Research Symposium S. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–63.
Peterson KA, Byrne KR, Vinson LA, Ying J, Boynton KK, Fang JC, Gleich GJ, Adler DG, Clayton F. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol. 2013;108:759–66.
Ueki S, Konno Y, Takeda M, Moritoki Y, Hirokawa M, Matsuwaki Y, Honda K, Ohta N, Yamamoto S, Takagi Y, et al. Eosinophil extracellular trap cell death-derived DNA traps: their presence in secretions and functional attributes. J Allergy Clin Immunol. 2016;137:258–67.
Kvarnhammar AM, Cardell LO. Pattern-recognition receptors in human eosinophils. Immunology. 2012;136:11–20.
Garcia-Martinez I, Santoro N, Chen Y, Hoque R, Ouyang X, Caprio S, Shlomchik MJ, Coffman RL, Candia A, Mehal WZ. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest. 2016;126:859–64.
Cianferoni A, Spergel J. Eosinophilic esophagitis: a comprehensive review. Clin Rev Allergy Immunol. 2015; https://doi.org/10.1007/s12016-015-8501-z.
Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109:1503–12.
Lim DM, Wang ML. Toll-like receptor 3 signaling enables human esophageal epithelial cells to sense endogenous danger signals released by necrotic cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G91–9.
Berin MC, Wang W. Reduced severity of peanut-induced anaphylaxis in TLR9-deficient mice is associated with selective defects in humoral immunity. Mucosal Immunol. 2013;6:114–21.
Marchesini G, Petta S, Dale Grave R. Diet, weight loss, and liver health in NAFLD: pathophysiology, evidence and practice. Hepatology. 2015; https://doi.org/10.1002/hep.28392.